David Sinclair recently reviewed human trials of anti-aging drugs Sinclair highlights metformins intriguing heart protection and immune function improvement NAD plus precursors like NMN and NR show promise in enhancing physical performance and reducing biological age GLP1R agonists potential in tackling diabetes obesity and age related diseases Rapamycin's dual role as an immunosuppressant and anti-aging agent is highlighted with promising results in immune response and inflammation reduction Dr Sinclair also sheds lights on spermadine and senolytics emphasizing their impact on cognitive function and cell rejuvenation For more on Sinclair's insights subscribe hit like and visit lifespan.io

Full Article:
[ Ссылка ]

свернуть